• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微卫星高度不稳定/dMMR 结直肠癌中淋巴结免疫应答的重要性。

Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer.

机构信息

Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Chiba, Japan.

Department of Colorectal Surgery, National Cancer Center Hospital East (NCCHE), Chiba, Japan.

出版信息

JCI Insight. 2021 May 10;6(9):137365. doi: 10.1172/jci.insight.137365.

DOI:10.1172/jci.insight.137365
PMID:33755600
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8262295/
Abstract

Patients with colorectal cancers (CRCs) generally exhibit improved survival through intensive lymph node (LN) dissection. However, recent progress in cancer immunotherapy revisits the potential importance of regional LNs, where T cells are primed to attack tumor cells. To elucidate the role of regional LN, we investigated the immunological status of nonmetastatic regional LN lymphocytes (LNLs) in comparison with those of the tumor microenvironment (tumor-infiltrating lymphocytes; TILs) using flow cytometry and next-generation sequencing. LNLs comprised an intermediate level of the effector T cell population between peripheral blood lymphocytes (PBLs) and TILs. Significant overlap of the T cell receptor (TCR) repertoire was observed in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) CRCs with high tumor mutation burden (TMB), although limited TCRs were shared between nonmetastatic LNs and primary tumors in microsatellite stable/MMR proficient (MSS/pMMR) CRC patients with low TMB. In line with the overlap of the TCR repertoire, an excessive LN dissection did not provide a positive impact on long-term prognosis in our MSI-H/dMMR CRC cohort (n = 130). We propose that regional LNs play an important role in antitumor immunity, particularly in MSI-H/dMMR CRCs with high TMB, requiring care to be taken regarding excessive nonmetastatic LN dissection in MSI-H/dMMR CRC patients.

摘要

结直肠癌(CRC)患者通过密集的淋巴结(LN)清扫通常可改善生存。然而,癌症免疫治疗的最新进展重新审视了区域 LN 的潜在重要性,T 细胞在那里被激活以攻击肿瘤细胞。为了阐明区域 LN 的作用,我们使用流式细胞术和下一代测序,比较非转移性区域 LN 淋巴细胞(LNL)与肿瘤微环境(肿瘤浸润淋巴细胞;TILs)的免疫状态。LNL 构成了外周血淋巴细胞(PBL)和 TIL 之间效应 T 细胞群体的中间水平。在具有高肿瘤突变负担(TMB)的微卫星不稳定高/错配修复缺陷(MSI-H/dMMR)CRC 中,观察到 T 细胞受体(TCR)库存在显著重叠,尽管在具有低 TMB 的微卫星稳定/错配修复功能正常(MSS/pMMR)CRC 患者中,非转移性 LNs 和原发性肿瘤之间共享的 TCR 有限。与 TCR 库的重叠一致,在我们的 MSI-H/dMMR CRC 队列(n=130)中,过度的 LN 清扫并未对长期预后产生积极影响。我们提出,区域 LN 在抗肿瘤免疫中发挥重要作用,特别是在具有高 TMB 的 MSI-H/dMMR CRC 中,需要注意在 MSI-H/dMMR CRC 患者中过度的非转移性 LN 清扫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/a19a6c6a0c3c/jciinsight-6-137365-g065.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/b0367e04898e/jciinsight-6-137365-g059.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/84eb78171751/jciinsight-6-137365-g060.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/fcc63432aa83/jciinsight-6-137365-g061.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/4bb246e9de0d/jciinsight-6-137365-g062.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/e83b2a15ace2/jciinsight-6-137365-g063.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/acd532d5a4be/jciinsight-6-137365-g064.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/a19a6c6a0c3c/jciinsight-6-137365-g065.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/b0367e04898e/jciinsight-6-137365-g059.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/84eb78171751/jciinsight-6-137365-g060.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/fcc63432aa83/jciinsight-6-137365-g061.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/4bb246e9de0d/jciinsight-6-137365-g062.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/e83b2a15ace2/jciinsight-6-137365-g063.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/acd532d5a4be/jciinsight-6-137365-g064.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869c/8262295/a19a6c6a0c3c/jciinsight-6-137365-g065.jpg

相似文献

1
Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer.微卫星高度不稳定/dMMR 结直肠癌中淋巴结免疫应答的重要性。
JCI Insight. 2021 May 10;6(9):137365. doi: 10.1172/jci.insight.137365.
2
Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.免疫疗法对错配修复缺陷型结直肠癌的疗效:从基础到临床。
Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188447. doi: 10.1016/j.bbcan.2020.188447. Epub 2020 Oct 6.
3
CD169 sinus macrophages in regional lymph nodes do not predict mismatch-repair status of patients with colorectal cancer.区域淋巴结中的 CD169 窦组织细胞不能预测结直肠癌患者错配修复状态。
Cancer Med. 2023 May;12(9):10199-10211. doi: 10.1002/cam4.5747. Epub 2023 Feb 27.
4
Immune microenvironmental heterogeneity according to tumor DNA methylation phenotypes in microsatellite instability-high colorectal cancers.根据微卫星不稳定高结直肠癌的肿瘤 DNA 甲基化表型的免疫微环境异质性。
Cancer Immunol Immunother. 2024 Sep 5;73(11):215. doi: 10.1007/s00262-024-03805-3.
5
Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.结直肠癌中的肿瘤浸润淋巴细胞:免疫治疗的基本指征和应用。
Front Immunol. 2022 Jan 14;12:808964. doi: 10.3389/fimmu.2021.808964. eCollection 2021.
6
Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.错配修复缺陷与免疫疗法在转移性结直肠癌中的作用
Curr Treat Options Oncol. 2016 Aug;17(8):41. doi: 10.1007/s11864-016-0414-4.
7
Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer.cGAS-STING 通路在调节错配修复缺陷/微卫星不稳定结直肠肿瘤免疫微环境中的作用。
Cancer Immunol Immunother. 2022 Nov;71(11):2765-2776. doi: 10.1007/s00262-022-03200-w. Epub 2022 Apr 16.
8
Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms.微卫星不稳定在错配修复功能健全的结直肠癌中的临床特征及潜在分子机制。
EBioMedicine. 2024 May;103:105142. doi: 10.1016/j.ebiom.2024.105142. Epub 2024 Apr 30.
9
Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer.Dickkopf-1 通过使错配修复缺陷的结直肠癌中 CD8+T 细胞失活来损害对 PD-1 阻断的肿瘤反应。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001498.
10
Prognosis and immunotherapy efficacy in dMMR&MSS colorectal cancer patients and an MSI status predicting model.错配修复缺陷/微卫星稳定型结直肠癌患者的预后和免疫治疗疗效及 MSI 状态预测模型。
Int J Cancer. 2024 Aug 15;155(4):766-775. doi: 10.1002/ijc.34946. Epub 2024 Apr 9.

引用本文的文献

1
Predictive value of combined DCE-MRI perfusion parameters and clinical features nomogram for microsatellite instability in colorectal cancer.联合DCE-MRI灌注参数和临床特征列线图对结直肠癌微卫星不稳定性的预测价值
Discov Oncol. 2025 May 23;16(1):892. doi: 10.1007/s12672-025-02705-x.
2
Unleashing the therapeutic potential of tumor-draining lymph nodes: spotlight on bladder cancer.释放肿瘤引流淋巴结的治疗潜力:聚焦膀胱癌
J Transl Med. 2025 Apr 29;23(1):489. doi: 10.1186/s12967-024-05864-7.
3
The Current Status of T Cell Receptor (TCR) Repertoire Analysis in Colorectal Cancer.

本文引用的文献

1
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.PD-1/PD-L1 检查点抑制肿瘤引流淋巴结中的 T 细胞免疫。
Cancer Cell. 2020 Nov 9;38(5):685-700.e8. doi: 10.1016/j.ccell.2020.09.001. Epub 2020 Oct 1.
2
Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy.通过局部给药阻断淋巴结中的免疫检查点可增强癌症免疫治疗效果。
Sci Transl Med. 2020 Sep 30;12(563). doi: 10.1126/scitranslmed.aay3575.
3
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
T细胞受体(TCR)库分析在结直肠癌中的现状
Int J Mol Sci. 2025 Mar 17;26(6):2698. doi: 10.3390/ijms26062698.
4
Phenotypic and spatial heterogeneity of CD8 tumour infiltrating lymphocytes.CD8 肿瘤浸润淋巴细胞的表型和空间异质性。
Mol Cancer. 2024 Sep 9;23(1):193. doi: 10.1186/s12943-024-02104-w.
5
Cell Identity and Spatial Distribution of PD-1/PD-L1 Blockade Responders.PD-1/PD-L1 阻断应答者的细胞身份和空间分布。
Adv Sci (Weinh). 2024 Nov;11(41):e2400702. doi: 10.1002/advs.202400702. Epub 2024 Sep 9.
6
Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms.错配修复 proficient 肿瘤足迹在免疫荒漠的沙中:机械约束和精确平台。
Front Immunol. 2024 Jul 19;15:1414376. doi: 10.3389/fimmu.2024.1414376. eCollection 2024.
7
Prognostic significance of negative lymph node count in microsatellite instability-high colorectal cancer.微卫星不稳定高结直肠癌中阴性淋巴结计数的预后意义。
World J Surg Oncol. 2024 Jul 19;22(1):186. doi: 10.1186/s12957-024-03469-4.
8
Prognostic and predictive value of examined lymph node count in stage III colorectal cancer: a population based study.III 期结直肠癌中检查淋巴结数的预后和预测价值:一项基于人群的研究。
World J Surg Oncol. 2024 Jun 13;22(1):155. doi: 10.1186/s12957-024-03404-7.
9
Survival analysis in pT1-3 and paracolic lymph-node invasion colorectal cancer: the prognostic role of positive paracolic lymph-node ratio for adjuvant chemotherapy.pT1-3 期和结肠旁淋巴结侵犯的结直肠癌的生存分析:阳性结肠旁淋巴结比率对辅助化疗的预后作用。
Clin Transl Oncol. 2024 Dec;26(12):2993-3002. doi: 10.1007/s12094-024-03470-z. Epub 2024 May 23.
10
Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy.肿瘤引流淋巴结:结直肠癌免疫治疗的机遇、挑战与未来方向。
J Immunother Cancer. 2024 Jan 19;12(1):e008026. doi: 10.1136/jitc-2023-008026.
效应 T 细胞和调节性 T 细胞之间的 PD-1 表达平衡可预测 PD-1 阻断疗法的临床疗效。
Nat Immunol. 2020 Nov;21(11):1346-1358. doi: 10.1038/s41590-020-0769-3. Epub 2020 Aug 31.
4
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.纳武利尤单抗对比化疗用于既往化疗后进展或不耐受的晚期食管鳞癌患者(ATTRACTION-3):一项多中心、随机、开放标签、III 期临床研究。
Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30.
5
Clonal replacement of tumor-specific T cells following PD-1 blockade.PD-1 阻断后肿瘤特异性 T 细胞的克隆性替换。
Nat Med. 2019 Aug;25(8):1251-1259. doi: 10.1038/s41591-019-0522-3. Epub 2019 Jul 29.
6
Cancer treatment and survivorship statistics, 2019.2019 年癌症治疗与生存统计
CA Cancer J Clin. 2019 Sep;69(5):363-385. doi: 10.3322/caac.21565. Epub 2019 Jun 11.
7
TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients.结直肠癌患者癌组织及肿瘤引流淋巴结的TCR测序分析
Oncoimmunology. 2019 Mar 22;8(6):e1588085. doi: 10.1080/2162402X.2019.1588085. eCollection 2019.
8
PD-1 regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.PD-1 阻断扩增的 PD-1 调节性 T 细胞促进癌症的过度进展。
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008. doi: 10.1073/pnas.1822001116. Epub 2019 Apr 26.
9
Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.肿瘤免疫抑制中的调节性 T 细胞——对癌症治疗的影响。
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371. doi: 10.1038/s41571-019-0175-7.
10
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.肿瘤引流淋巴结在 PD-1/PD-L1 检查点治疗中起着关键作用。
JCI Insight. 2018 Dec 6;3(23):124507. doi: 10.1172/jci.insight.124507.